

Non-clinical development of an antibody-drug conjugate(ADC) for solid tumors targeting Src kinase-related transmembrane proteins

Aimedbio Inc.



ONCOLOGY	Preclinical
Product Type	Antibody
Indication	Lung cancer, Breast cancer, Colon cancer, Bladder cancer
Target	Target A
MoA(Mechanism of Action)	Binding to cell surface antigen → Receptor mediated endocytosis → Lysosomal degradation → Active payload release → Cell death and Bystander killing effect
Competitiveness	<ul style="list-style-type: none"> • Best-in-Class, ADC - Superior cellular internalization and target degradation with high affinity. - Composed of a novel antibody and payload. - Demonstrates superior anti-tumor efficacy in solid tumors compared to the Standard of Care (SoC). - High tolerability in NHP (non-human primate) study.
Development Stage	Preclinical
Route of Administration	Intravenous (i.v)

Any unauthorized distribution or reproduction of this material is strictly prohibited.